Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis
This NMA revealed that cases with EGFR-mutated NSCLC may benefit from different first-line treatment regimens according to their clinicopathological characteristics. On the whole, osimertinib plus CT and amivantamab plus lazertinib emerged as the most noticeable treatment modalities for such cases. (PROSPERO ID: CRD42024506995).
Authors
- Qinghua Zhou (ORCID: https://orcid.org/0000-0002-1108-9456)
- Ting Wang (ORCID: https://orcid.org/0000-0001-7414-5390)
- Ting Mei
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1186/s12885-025-15236-z
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00